{"organizations": [], "uuid": "369fcd09c0b97510bcf4b1863d298f408ff1f08a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-corsair-pharma-and-united-therapeu/brief-corsair-pharma-and-united-therapeutics-enter-into-strategic-collaboration-to-advance-novel-treprostinil-prodrugs-idUSFWN1OY02B", "country": "US", "domain_rank": 408, "title": "BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T13:11:00.000+02:00", "replies_count": 0, "uuid": "369fcd09c0b97510bcf4b1863d298f408ff1f08a"}, "author": "", "url": "https://www.reuters.com/article/brief-corsair-pharma-and-united-therapeu/brief-corsair-pharma-and-united-therapeutics-enter-into-strategic-collaboration-to-advance-novel-treprostinil-prodrugs-idUSFWN1OY02B", "ord_in_thread": 0, "title": "BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-corsair pharma and united therapeutics enter into strategic col", "sentiment": "negative"}, {"name": "brief-corsair pharma and united therapeutics", "sentiment": "negative"}, {"name": "advance novel treprostinil prodrugs reuters staff  jan", "sentiment": "none"}, {"name": "united therapeutics", "sentiment": "none"}, {"name": "united therapeutics corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "united therapeutics corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 12 AM / Updated 3 minutes ago BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs Reuters Staff \nJan 3 (Reuters) - United Therapeutics Corp: \n* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS \n* UNITED THERAPEUTICS SAYS GRANTED EXCLUSIVE LICENSE TO CORSAIR‘S INTELLECTUAL PROPERTY FOR DEVELOPMENT OF TREPROSTINIL PRODRUG FORMULATIONS \n* UNITED THERAPEUTICS CORP - MADE MINORITY EQUITY INVESTMENT IN CORSAIR THAT INCLUDES AN OPTION TO ACQUIRE REMAINING OUTSTANDING SHARES OF CORSAIR \n* UNITED THERAPEUTICS SAYS UNDER TERMS OF LICENSE AGREEMENT, CORSAIR RECEIVED UPFRONT CONSIDERATION \n* UNITED THERAPEUTICS- CORSAIR IS ENTITLED TO ROYALTY PAYMENTS ON COMMERCIALIZATION OF TREPROSTINIL PRODRUG PRODUCTS BY CO COVERED BY CORSAIR‘S PATENTS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-03T13:11:00.000+02:00", "crawled": "2018-01-03T13:25:30.068+02:00", "highlightTitle": ""}